Becton, Dickinson and Company (NYSE:BDX) attempts to attain leading position in street, Shares price changes as it -2.40% to close at $213.25 with the total traded volume of 1.01 Million shares. A leading global medical technology company, BD (NYSE:BDX) reported that it is updating the instructions for use of certain BD Vacutainer®tubes as part of its quality process to ensure that customers understand the appropriate uses of these products.
Since BD became aware of the concerns about inaccurate lead test results from Magellan Diagnostics LeadCare Testing Systems, the company has been cooperating fully with the U.S. Food and Drug Administration (FDA). BD launched an internal investigation and determined that Anodic Stripping Voltammetry (ASV) technology, which is used in Magellan LeadCare testing systems, is not compatible with thiuram, a material found in the rubber stoppers of the BD Vacutainer® EDTA Lavender, Pink and Tan top tubes and BD Vacutainer® Lithium Heparin Green top tubes. Thiuram has been in these rubber stoppers since 1996, however, the effect of thiuram on lead testing when used with ASV technology was only recently observed through the course of this investigation. As a result, BD is updating the instructions for use of its BD Vacutainer® Lavender, Pink and Tan top tubes and BD Vacutainer® Lithium Heparin Green top tubes to include a precaution that these products are not recommended for lead testing when using Magellan Diagnostics LeadCare® assays employing the ASV methodology, or any other assay employing ASV methodology. Other lead testing systems, such as graphite furnace atomic absorption spectroscopy (GFAAS) and inductively coupled plasma mass spectrometry (ICP-MS) are not affected by this update. In addition, BD is not aware of any other instrumentation that uses ASV technology. BD Vacutainer® tubes have been on the market for more than 60 years and continue to have a track record of safe and effective use.
There is no need for customers to return any products to BD, and these products can continue to be used in accordance with the updated instructions for use. Customers should continue to follow FDA’s safety communication for testing lead levels, which currently recommends that no venous blood should be tested with Magellan’s LeadCare test systems (regardless of the collection tube used). The firm has institutional ownership of 86.20%, while insider ownership included 0.30%. Its price to sales ratio ended at 4.65. BDX attains analyst recommendation of 2.10 with week’s performance of -4.86%.
JPMorgan Chase & Co. (NYSE:JPM) moved down reacts as active mover, shares a loss -4.17% to traded at $109.95 and the percentage gap between open changing to regular change was -1.34%. JPMorgan Chase (JPM) reported that CEO executive Jamie Dimon earned as much in a day as the typical employee at his bank took home in the whole of last year, putting him near the top of an emerging league table of big bank CEO pay. In an annual proxy filing after the market close on Wednesday, the biggest US bank by assets said that its chairman and CEO was paid $28.3m last year, or 364 times the median employee, who received $77,799, including firm-paid benefits.
MrDimon’s pay ratio of 364 times the median worker puts him second in the list for the big banks, according to Autonomous Research, behind Citigroup chief Mike Corbat, whose pay of $17.8m last year was 369 times the median worker. Charlie Scharf of Bank of New York Mellon, a protégé of MrDimon who arrived at BNY in the summer of last year, ranks third, with a $20m package 354 times the average worker. The firm past twelve months price to sales ratio was 5.92 and price to cash ratio remained 0.36. As far as the returns are concern, the return on equity was recorded as 9.80% and return on investment was 6.90% while its return on asset stayed at 0.90%. The firm has total debt to equity ratio measured as 1.24.